4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
3.330
-0.010 (-0.30%)
Apr 28, 2025, 4:00 PM EDT - Market closed

Company Description

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.

Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.

The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease.

4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V.

The company was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics logo
Country United States
Founded 2013
IPO Date Dec 11, 2020
Industry Biotechnology
Sector Healthcare
Employees 227
CEO David Kirn

Contact Details

Address:
5858 Horton Street, Suite 455
Emeryville, California 94608
United States
Phone 510 505 2680
Website 4dmoleculartherapeutics.com

Stock Details

Ticker Symbol FDMT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $23.00
CIK Code 0001650648
CUSIP Number 35104E100
ISIN Number US35104E1001
Employer ID 47-3506994
SIC Code 2836

Key Executives

Name Position
Dr. David H. Kirn M.D. Co-Founder, Chief Executive Officer and Director
Dr. John F. Milligan Ph.D. Executive Chairman
Dr. Fariborz Kamal Ph.D. President and Chief Operating Officer
Dr. Noriyuki Kasahara M.D., Ph.D. Chief Scientific Officer
Dr. Robert Y. Kim M.B.A., M.D. Chief Medical Officer
Theresa Janke Co-Founder and Chief of Staff
Uneek Mehra Chief Financial and Business Officer
Dr. Scott P. Bizily J.D., Ph.D. Chief Legal Officer and Corporate Secretary
Dr. An Song Ph.D. Chief Development Officer
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D. Senior Vice President and Therapeutic Area Head of Pulmonology

Latest SEC Filings

Date Type Title
Apr 17, 2025 SCHEDULE 13G/A Filing
Mar 24, 2025 EFFECT Notice of Effectiveness
Feb 28, 2025 POS AM Post-Effective amendments for registration statement
Feb 28, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 28, 2025 10-K Annual Report
Feb 28, 2025 8-K Current Report
Feb 28, 2025 POSASR Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing